For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulat
Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved biosimilar in Europe, which is due to launch after the drug loses EU patent protec
Teva and partner Alvotech’s hopes of launching their biosimilar of AbbVie’s high-potency formulation of big-selling immunology drug Humira have been dashed, after the FDA